6
Oct
2026

Adalvo

Exhibitor at CPHI Milan 2026 stand 18A1, Finished Dosage & Formulation
About Us

Adalvo is a leading B2B pharmaceutical company in Europe with over 110 global partners in 100+ countries. The company's goal is to improve patient care by providing high-quality products and services through a smart collaboration network. Adalvo's unique approach is tailored to each partner, helping them grow their business and achieve their objectives, whether that's increasing revenue or expanding into new markets. The company also prioritizes employee development and community growth while striving for excellence. Adalvo's commitment to excellence and making a difference ensures that it remains a key player in the competitive pharmaceutical industry.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Malta
  • On CPHI since:
    2020
  • Certificates:
    1
  • Employees:
    100 - 249
Company types
Other
Primary activities
Out-licensing specialist
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 18A1, Finished Dosage & Formulation

Adalvo Limited Resources (1)

  • Adalvo announces successful DCP Submission for Desogestrel + Ethinylestradiol (0.15mg+0.02mg) film coated tablets

    Datasheet Adalvo announces successful DCP Submission for Desogestrel + Ethinylestradiol (0.15mg+0.02mg) film coated tablets

    We are pleased to announce our successful DCP submission for Desogestrel+Ethinylestradiol (0.15mg+0.02mg) film-coated tablets.

    This accomplishment enables Adalvo to provide multiple treatment options to both partners and patients.

    Our Desogestrel+Ethinylestradiol 0.15mg/0.02mg film-coated tablets were developed in collaboration with one of our strategic partners, based on the reference brand Mercilon film-coated tablets. The product is a low-dose contraceptive used by women to prevent pregnancy.

    According to IQVIA, Desogestrel+Ethinylestradiol (0.15mg+0.02mg) generated approximately $85mn in global sales in 2022.

    Building on this accomplishment, Adalvo continues to expand their Women's Health portfolio. As a distinguished player in this domain, we are delighted to offer a wide range of products, as outlined below:

    Cyproterone + Ethinylestradiol, 2 mg + 0.035 mgDesogestrel, 75 mcgDesogestrel +...